Breaking News

Byondis Partners with Medac to Commercialize Antibody-Drug Conjugate

SYD985 targets a range of HER2-expressing cancers such as metastatic breast and endometrial (uterine) tumors.

Author Image

By: Charlie Sternberg

Associate Editor

Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company, has entered into a License and Collaboration Agreement and a Supply Agreement with medac GmbH, a privately owned pharmaceutical company based in Germany.   Byondis and medac are partnering to commercialize Byondis’ lead program, anti-HER2 antibody-drug conjugate (ADC) trastuzumab duocarmazine (SYD985), pending approval by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulator...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters